About CNS Pharmaceuticals
CNS Pharmaceuticals is a company based in Houston (United States) founded in 2017.. The company has 5 employees as of December 31, 2024. CNS Pharmaceuticals offers products and services including Berubicin and TPI 287.
- Headquarter Houston, United States
- Employees 5 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cns Pharmaceuticals, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-14.86 M21.18as on Dec 31, 2024
-
EBITDA
$-14.9 M21.01as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
5
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CNS Pharmaceuticals
CNS Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol CNSP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of CNS Pharmaceuticals
CNS Pharmaceuticals offers a comprehensive portfolio of products and services, including Berubicin and TPI 287. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
First anthracycline to cross blood-brain barrier for glioblastoma treatment.
Novel taxane permeable to blood-brain barrier for brain malignancies.
Funding Insights of CNS Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by CNS Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CNS Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cns Pharmaceuticals Comparisons
Competitors of CNS Pharmaceuticals
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cns Pharmaceuticals
Frequently Asked Questions about CNS Pharmaceuticals
When was CNS Pharmaceuticals founded?
CNS Pharmaceuticals was founded in 2017.
Where is CNS Pharmaceuticals located?
CNS Pharmaceuticals is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Who is the current CEO of CNS Pharmaceuticals?
John Climaco is the current CEO of CNS Pharmaceuticals.
How many employees does CNS Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at CNS Pharmaceuticals is 5.
What does CNS Pharmaceuticals do?
CNS Pharmaceuticals was founded in 2017 in Houston, United States, focusing on the oncology sector. A pipeline of anti-cancer drug candidates is maintained, including berubicin, which crosses the blood-brain barrier to target tumor cells, and TPI 287, aimed at glioblastoma multiforme. Efforts are directed toward primary and metastatic cancers in the brain and central nervous system, with operations centered on drug development for these indications.
What products or services does CNS Pharmaceuticals offer?
CNS Pharmaceuticals offers Berubicin and TPI 287.
Is CNS Pharmaceuticals publicly traded?
Yes, CNS Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol CNSP.
What is CNS Pharmaceuticals's ticker symbol?
The ticker symbol of CNS Pharmaceuticals is CNSP on NASDAQ.